Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Abstract Text:

    i sekineI Sekine,h nokiharaH Nokihara,k takedaK Takeda,y nishiwakiY Nishiwaki,k nakagawaK Nakagawa,h isobeH Isobe,k moriK Mori,k matsuiK Matsui,n saijoN Saijo,t tamuraT Tamura,i sekineI Sekine,h nokiharaH Nokihara,k takedaK Takeda,y nishiwakiY Nishiwaki,k nakagawaK Nakagawa,h isobeH Isobe,k moriK Mori,k matsuiK Matsui,n saijoN Saijo,t tamuraT Tamura,

    Patients with previously untreated extensive-disease small-cell lung cancer were treated with irinotecan 60 mg m(-2) on days 1 and 8 and cisplatin 60 mg m(-2) on day 1 with (n=55) or without (n=54) etoposide 50 mg m(-2) on days 1-3 with granulocyte colony-stimulating factor support repeated every 3 weeks for four cycles. The triplet regimen was too toxic to be considered for further studies.British Journal of Cancer (2008) 98, 693-696. doi:10.1038/sj.bjc.6604233 www.bjcancer.com Published online 5 February 2008.

    Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Publishing Authors By Initials

    i sekineI Sekine,h nokiharaH Nokihara,k takedaK Takeda,y nishiwakiY Nishiwaki,k nakagawaK Nakagawa,h isobeH Isobe,k moriK Mori,k matsuiK Matsui,n saijoN Saijo,t tamuraT Tamura,i sekineI Sekine,h nokiharaH Nokihara,k takedaK Takeda,y nishiwakiY Nishiwaki,k nakagawaK Nakagawa,h isobeH Isobe,k moriK Mori,k matsuiK Matsui,n saijoN Saijo,t tamuraT Tamura,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: British journal of cancer

    VOLUME: 98

    Page Numbers: 693-6

    Journal Abbreviation: Br. J. Cancer

    ISSN: 0007-0920

    DAY: 5

    MONTH: 02

    YEAR: 2008

    Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 370635

    Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.

    AFFILIATION: 1Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Br J Cancer

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News